GlobeNewswire

Compuware and Wipro Jointly Launch a Mainframe Center of Excellence

Dela

Best Practices Empower Large Global Enterprises to Better Leverage High-Value Systems of Record in Fast-Moving Digital Markets

  • Modernized mainframe systems of record are critical digital investments for large global enterprises-delivering unmatched reliability, scalability, performance and security.
  • Unfortunately, outdated processes and tools often prevent enterprises from adapting their existing mainframe applications to meet changing business needs with the same agility achieved on other platforms.
  • Compuware and Wipro are addressing this challenge through a joint Mainframe Center of Excellence (CoE) that enables Wipro to formulate best practices for achieving mainframe agility and cross-platform DevOps integration, as well as gain mastery of Compuware's software.
  • By leveraging Compuware's software and Wipro's best practices, enterprises can gain the combined competitive advantages of scale and speed, while also successfully navigating a difficult generational shift in mainframe stewardship.

DETROIT, July 25, 2017 (GLOBE NEWSWIRE) --  Compuware Corporation today announced the launch of a Mainframe Center of Excellence (CoE) in partnership with Wipro Limited (NYSE:WIT) (BSE:507685) (NSE:WIPRO), a leading global information technology, consulting and business process services company. The Mainframe CoE will be dedicated to helping large global enterprises better leverage their systems of record for competitive advantage in fast-moving digital markets.

Enterprise IT leaders grapple with mainframe environments that are mired in traditional "waterfall" development, inadequately integrated into cross-platform DevOps workflows and foreign to the Millennials who will ultimately be responsible for the platform's future. The innovative Mainframe CoE, which Wipro will operate, strengthens the company's ability to transform customers' mainframe environments and drive competitive advantage through the adoption of cross-platform Agile and DevOps best practices.  

Compuware is enabling Wipro technical consultants, via hands-on access to Compuware's proven solutions and ongoing training, to establish industry-leading expertise in: agile development on the mainframe, integration of mainframe dev/test/release processes into multi-platform enterprise DevOps toolchains, and modernized workspaces that empower Millennials to effectively work with mainframe resources in the same manner as they work with other platforms. Wipro's extensive experience along with this deep expertise of Compuware's mainframe software, will provide an empirical foundation for the CoE's best-practice recommendations.

The collaboration also serves as another resource for continual improvement towards an Agile mainframe. With direct experience using Compuware's products to discover better ways to leverage mainframe applications and data, Wipro can assist their enterprise clientele in achieving greater innovation throughput and quality that's essential to competing in the digital age.

Benefits to enterprise customers include:

  • Dramatically improved digital agility
  • Substantial reductions in mainframe TCO
  • Greater business value and competitive differentiation from investments in mainframe applications, data and processing power
  • Successful transition of mainframe stewardship from Baby Boomers to less specifically mainframe-experienced Millennials

For large global enterprises, mainframes are irreplaceable and invaluable systems of record. They are repositories of business logic, customer data and other intellectual property that have been carefully and continuously honed over many decades. Unfortunately, a combination of outmoded processes, tools and culture renders many enterprises incapable of quickly adapting their systems of record as necessary to fulfill the relentlessly changing needs of the business.

This lack of speed is in marked contrast to the Agile, DevOps and Continuous Delivery disciplines that they have been able to apply to applications running on other platforms such as private and public clouds. This can greatly hamper competitiveness of large enterprises vis-a-vis smaller, nimbler companies. The new Mainframe CoE addresses this critical challenge by capturing and sharing best practices for optimizing mainframe agility and mainstreaming of the mainframe into broader multi-platform enterprise architectures. 

"Compuware's focus on mainframe Agility and DevOps enablement aligns with our own approach to mainframe applications. We believe this CoE will accelerate the digital journeys for our global clients especially those of large enterprises," said Jatin Mehta, Head, Mainframe Application Services, Wipro Limited. "By leveraging Compuware's technology in the context of a broader enterprise strategy for digital excellence, Wipro can substantially enhance our enterprise customers' ability to innovate in a marketplace where rapid parity is a must," he added.

"Partnering with Wipro on a mainframe-centric CoE affords us a great opportunity to demonstrate exactly how our technology supports the kind of aggressive evolution enterprises absolutely must bring to bear on their mainframes. This will be key to their ability to survive and thrive in an innovation-based economy," said Compuware CEO Chris O'Malley. "We look forward to a long and fruitful collaboration with Wipro-which clearly has tremendous visibility into both the nature of the enterprise's current mainframe challenges and the path to helping these users overcome those challenges in a timely manner."

Compuware Corporation
Compuware empowers the world's largest companies to excel in the digital economy by fully leveraging their high-value mainframe investments. We do this by delivering highly innovative solutions that uniquely enable IT professionals with mainstream skills to manage mainframe applications, data, and platform operations. Learn more at compuware.com.

Follow us on:

Press Contact
Kristina LeBlanc, The Medialink Group, kristinawleblanc@gmail.com, (508) 930-5636
Mary McCarthy, Public Relations Manager, Compuware, mary.mccarthy@compuware.com, (313) 227-7088

For Sales and Marketing Information
Compuware Corporation, One Campus Martius, Detroit MI 48226, 800-521-9353, compuware.com.

Copyright © 2017 Compuware Corporation. Compuware, the Compuware logo, and Topaz are registered or pending registration with the U.S. Patent and Trademark Office, and may be registered or pending registration in other countries.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Compuware Corporation via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Oboya signs a cooperation agreement with Gaia regarding biomaterials13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") has signed an important and long-term cooperation agreement on environmentally friendly biomaterials with Gaia Biomaterials AB ("Gaia") in Helsingborg, Sweden. The agreement means that Oboya uses Gaias biomaterials for the production and development of environmentally friendly cultivation products for the cultivation industry. Oboya has been actively involved in innovation, environmental and sustainability issues in recent years, and our goal is to encourage environmental and sustainability in the cultivation industry by offering environmentally friendly cultivation products to our customers. Oboya believes that the use of biomaterials will be important for success in the conversion to a fossil-free cultivation industry worldwide. The cooperation agreement means that Oboya uses Gaias biomaterials in its production and that through Gaias expertise we can develop new environmentally friendly cultivation products. Gaias biomaterials are bi

Oboya tecknar ett samarbetsavtal med Gaia avseende biomaterial13.12.2018 11:41Pressmeddelande

Oboya Horticulture Industries AB (publ) ("Oboya") har tecknat ett viktigt och långsiktigt samarbetsavtal avseende miljövänligt biomaterial med Gaia Biomaterials AB ("Gaia") i Helsingborg, Sverige. Avtalet innebär att Oboya använder Gaias biomaterial för tillverkning och utveckling av miljövänliga odlingsprodukter till odlingsindustrin. Oboya har under de senaste åren arbetat aktivt med innovation, miljö- och hållbarhetsfrågor och vårt mål är att främja miljö och hållbarhet inom odlingsindustrin genom att erbjuda miljövänliga odlingsprodukter till våra kunder. Oboya anser att användningen av biomaterial kommer att vara viktigt för framgång i omställningen till en fossilfri odlingsindustri världen över. Samarbetsavtalet innebär att Oboya använder Gaias biomaterial i sin produktion och att vi genom Gaias kompetens kan utveckla nya miljövänliga odlingsprodukter. Gaias biomaterial är biologiskt nedbrytbart, komposterbart samt ger upp till 80 % lägre koldioxidutsläpp vid förbränning jämfört

Stillfront: Simutronics reclaims publishing services10.12.2018 14:11Pressmeddelande

PRESS RELEASE December 10, 2018 Simutronics reclaims the publishing services for SIEGE: Titan Wars globally except China Simutronics Corp, a studio within Stillfront Group AB, has ended a co-publishing agreement regarding the mobile game SIEGE: Titan Wars with New York based publishing partner Tilting Point. According to a new agreement, Tilting Point will continue to provide publishing services and market the game in China but Simutronics will run the publishing services and marketing globally from the Group going forward. Simutronics is a leading developer of online roleplaying and mobile games such as DragonRealms, GemStone IV and Lara Croft Relic Run, the latter with more than 23 million downloads. Tilting Point is a new-generation games partner that provides top development studios with expert resources, services, and operational support to optimize high quality live games for success. "I am very pleased to continue the partnership with Tilting Point for the Chinese market as this

Stillfront: Simutronics återtar förläggartjänster10.12.2018 14:11Pressmeddelande

PRESSMEDDELANDE 2018-12-10 Simutronics återtar förläggartjänster för SIEGE: Titan Wars globalt med undantag för Kina Simutronics, en studio inom Stillfront Group, har avslutat ett medförläggaravtal avseende mobilspelet SIEGE: Titan Wars med den New York-baserade förläggarpartnern Tilting Point. Enligt ett nytt avtal kommer Tilting Point fortsatt att tillhandahålla förläggartjänster och marknadsföring av spelet i Kina men på global nivå kommer Simutronics att ansvara för förläggartjänster och marknadsföring av spelet från gruppen. Simutronics är en ledande utvecklare av rollspel och mobila spel som till exempel DragonRealms, GemStone IV och Lara Croft Relic Run, den sistnämnda med mer än 23 miljoner nedladdningar. Tilting Point är den nya generationens spelbolagspartner som förser ledande utvecklingsstudios med expertis, tjänster och operationell support för att optimera högkvalitativa livespel framgångsrikt. "Jag är mycket nöjd över det fortsatta partnerskapet med Tilting Point för den

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

Karolinska Development's portfolio company Aprea Therapeutics presents continued positive results from a Phase Ib/II study of APR 2462.12.2018 18:00Pressmeddelande

STOCKHOLM, December 2, 2018. Karolinska Development's portfolio company Aprea Therapeutics today presented positive clinical results for its drug candidate APR 246 at the 2018 American Society of Hematology (ASH) Annual Meeting in San Diego, US. An Overall Response Rate of 95% and a Complete Remission (CR) rate of 70% were achieved in an ongoing Phase I/II combination study of APR 246 and azacitidine (AZA) for the treatment of TP53 mutated Myelodysplastic Syndrome (MDS). No dose-limiting toxicities have been observed. Based on these encouraging data, Aprea intends to progress APR 246 into a Phase III study in the near future. The results presented at the ASH meeting is based on 20 patients with TP53 mutated MDS. The overall response rate was 95%, and 14 (70%) patients achieved a complete remission at data cutoff. These findings were accompanied by a deep molecular remission in the majority of patients as assessed by serial TP53 analysis. No dose-limiting toxicities have been experience

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum